Thank you, Russell. We had a very strong quarter and a great start to 2025. We grew our organic sales 3.6% in the quarter, which was led by our Americas and Asia region with excellent growth of 5.1%, while our Europe and Australia region returned to growth this quarter at 0.7%. We also reported strong growth in our adjusted pretax income as well as our adjusted diluted earnings per share in the quarter, while funding an increase in R&D and expanding our sales force, and we finished in a net cash position even after funding acquisitions. So we're off to a great start this year. We'll start on Slide #4 for our quarterly sales trends. Organic sales grew 3.6% in the quarter. Acquisitions net of divestitures added 8.8% and foreign currency translation increased sales by 1.2% for total sales growth of 13.6% in the quarter. Turning to Slide #5. This details our quarterly gross margin trending. Our gross profit margin was 50.3% this quarter compared to 51.7% in the first quarter of last year. We closed on the acquisition of Gravotech this quarter, which Russell just mentioned, and this resulted in purchase accounting adjustments to recognize the fair value of inventory acquired and this reduced our gross profit margin by approximately 110 basis points in the quarter. Without this nonrecurring adjustment, our gross profit margin would have been 51.4%, which is approximately in line with the prior year. Our gross profit margin continues to be strong as we realized benefit from our sales growth being led by our highest gross profit margin products. Moving to Slide #6, you'll find our SG&A expense trending. SG&A was $111.8 million this quarter compared to $96.3 million in the first quarter of last year. As a percent of sales, SG&A increased to 29.7% compared to 29% last Q1. If you exclude amortization expense from each of the periods presented as well as other nonrecurring acquisition-related costs incurred in the current quarter, and SG&A would have been 28.3% of sales, both this quarter and in the first quarter of last year. We continue to invest in growth by expanding our sales force, enhancing our digital capabilities and broadening our omnichannel strategies, while identifying efficiencies throughout our back-end sales and other support functions. On Slide #7, you'll find the trending of our investments in research and development. We continue to increase our investment in R&D within our organic business and through the acquisition of Gravotech. R&D expense was $18.9 million, which was 5% of sales this quarter, an increase from $15.7 million or 4.7% of sales last year. Our best ROI almost always comes from our highly engineered products, and we really do have a very exciting line of products set to launch this year. Moving along to Slide #8, you'll find the trending of our pretax earnings. Pretax earnings on a GAAP basis decreased slightly from $59.4 million to $58.8 million in the quarter. But if you exclude amortization from both periods and other acquisition-related charges that we incurred in the current quarter, Pretax earnings increased 11% from $61.8 million to $68.6 million. Turning to Slide #9, you'll find the trending of our net earnings and EPS. Similar to pretax earnings, our net income decreased slightly due to the incremental amortization and other nonrecurring acquisition-related charges that we incurred in the quarter. Our reported GAAP diluted earnings per share was consistent with the prior year at $0.97 per share. But if you exclude amortization from both periods as well as the other acquisition-related charges from the current period, our adjusted net income grew from $49.1 million to $54.2 million, which is an increase of 10.4%, and our adjusted diluted EPS grew from $1 per share to $1.12 per share, an increase of 12%. So we had another strong earnings quarter resulting from our organic sales growth and our ongoing focus on efficiencies. On Slide #10, you'll find a summary of our cash generation. Operating cash flow was $23.4 million in the first quarter this year compared to $62.3 million in the first quarter last year. Free cash flow was $16.1 million in Q1 of this year compared to $51 million in last year's Q1. Operating cash flow was down this quarter mainly due to a timing shift in certain vendor payments, some of which was within Gravotech. We were also reducing inventory at this time last year, which provided a larger working capital benefit than we would typically expect to realize. We've returned to more normalized levels of inventory following the supply chain challenges from a couple of years ago, so we don't expect large working capital changes apart from periodic short-term timing items like we saw this quarter. Slide #11 details the impact that our historical cash generation has had on our balance sheet. As of October 31, we were in a net cash position of $29 million. Our approach to capital allocation is consistent, and that is to first use our cash to fund organic sales growth and efficiency opportunities. This includes investing in new product development, sales generating resources, capability-enhancing CapEx and automation focused CapEx. We have the ability to invest throughout the economic cycle so that we're always positioned to drive future sales growth and profit improvements. And second, we focus on consistently increasing our dividends. In September, we announced our 39th consecutive year of annual dividend increase, which is a street that we're very proud of. After funding organic investments and dividends, we then deploy our cash in a disciplined manner for acquisitions, where there are synergies and for opportunistic share buybacks. Our strong balance sheet puts us in a position to be able to increase our investment in R&D and other organic sales opportunities to acquire companies strategically and to return funds to our shareholders through dividends and share buybacks. Turning to Slide #12, you'll find our fiscal 2025 guidance. For maintaining our full year fiscal 2025 previously announced adjusted diluted EPS guidance range of $4.40 per share to $4.70 per share. Our GAAP EPS guidance range was adjusted for amortization and other acquisition-related charges, which we now expect to range from $4.02 to $4.32 per share. Our adjusted diluted EPS guidance range represents a range of growth of between 4.3% to 11.4% over 2024. We also anticipate organic sales growth in the low single-digit percentages for the year ending July 31, 2025. Other elements of our guidance include an income tax rate of approximately 20%, depreciation and amortization expense of approximately $40 million and capital expenditures of approximately $35 million. Potential risks to our guidance, among others, include potential strengthening of the U.S. dollar, inflationary pressures that were unable to offset in a timely enough manner or an overall slowdown in economic activity. I'll now turn the call back over to Russell to cover our regional results and to provide some closing thoughts before Q&A. Russell?